Steward Partners Investment Advisory’s Taysha Gene Therapies TSHA Stock Holding History

Steward Partners Investment Advisory’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.4K	Buy	+3,000	New	+$17.8K	﹤0.01%	3404

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Steward Partners Investment Advisory's TSHA Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 3,000 shares worth $20.4K. The stake represents ﹤0.01% of the portfolio and ranks #3404 among its holdings.

137 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Steward Partners Investment Advisory held 3,000 shares of Taysha Gene Therapies worth $20.4K as of Q2 2026.
Taysha Gene Therapies was a new Steward Partners Investment Advisory position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3404 holding.
137 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.